Figure 2.

(A) Swimmer’s plot of time (months) on first-line treatment with clinical response for evaluable patients (n = 19). Clinical response is represented as follows: progressive disease (PD), stable disease (SD), partial response (PR), and complete response (CR); (B) Kaplan–Meier curve of progression free survival (PFS) among all BRAF-alteration positive patients. Table indicates median PFS in each BRAF class. Carbo: carboplatin; Pem: pemetrexed; Atezo: atezolizumab; Cis: cisplatin; Chemo: chemotherapy; Pt: patient; FU: follow-up.